DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 22.3% from a year ago
Property, plant & equipment (net) stood at $317K at the end of Q1 FY2026, down 22.3% from a year earlier and down 7.3% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.
Context
- Property, plant & equipment (net) amounted to 0.6% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -22.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 342K USD
- Year-over-year change
- -19.9%
- 4-year CAGR
- +32.2%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 342K | -19.9% |
| FY2024 | 2024-12-31 | 427K | -12.0% |
| FY2023 | 2023-12-31 | 485K | -13.4% |
| FY2022 | 2022-12-31 | 560K | +400.0% |
| FY2021 | 2021-12-31 | 112K | — |
Property, Plant & Equipment (Net) vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 property, plant & equipment (net) of $317K is the lowest of the 7 companies compared; the peer median is $13.88M.
- Its year-over-year change of -22.3% is the 6th highest of 7, against a peer median of -10.4%.
- Property, plant & equipment (net) amounts to 0.6% of total assets for DMAC, versus a peer median of 3.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $113.42M | -12.8% | +17.2% | 9.8% | |
| Mar 2026 | $57.88M | +24.7% | +61.4% | 19.8% | |
| Mar 2026 | $23.97M | -16.8% | -15.2% | 5.7% | |
BIOABioAge Labs, Inc. | Mar 2026 | $3.8M | -8.0% | +115.6% | 1.0% |
| Mar 2026 | $3.42M | -62.1% | — | 0.9% | |
| Mar 2026 | $861K | +43.3% | +0.0% | 1.3% | |
| Mar 2026 | $317K | -22.3% | -15.2% | 0.6% | |
| Peer median (excluding DMAC) | $13.88M | -10.4% | +17.2% | 3.5% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.